The safety of sodium ferric gluconate complex in haemodialysis patients has been extensively evaluated [5]

Nephrology Dialysis Transplantation

Volumn 20, Issue 8, 2005, Pages 1770-

  Michael, Beckie ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; IRON DERIVATIVE; IRON DEXTRAN; PLACEBO;

ANAPHYLAXIS; BACKACHE; CLINICAL TRIAL; DIAPHORESIS; DOSE RESPONSE; DRUG HYPERSENSITIVITY; DRUG SAFETY; HEMODIALYSIS PATIENT; HUMAN; HYPOTENSION; LETTER; NAUSEA; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; TASTE DISORDER; VASODILATATION; VOMITING; WHEEZING;

FERRIC COMPOUNDS; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; RENAL DIALYSIS;

EID: 26444596187     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfh936     Document Type: Letter

References (5)

1. Bhowmik D, Tiwari SC. Do we need to change our administration practice with regard to sodium ferric gluconate complex in glucose? Nephrol Dial Transplant 2005
2. Michael B, Coyne DW, Fishbane S et al. Sodium ferric gluconate complex in hemodialysis patients: Adverse reactions compared to placebo and iron dextran. Kidney Int 2002; 61: 1830-1839
3. Michael B, Coyne DW, Folkert VW, Dahl NV, Warnock DG. Sodium ferric gluconate complex in hemodialysis patients: A prospective evaluation of long-term safety. Nephrol Dial Transplant, 2004; 19: 1576-1580
4. Coyne DW. Parenteral iron safety and the special article 'Just the FAQs: frequently asked questions about iron and anemia in patients with chronic kidney disease'. Am J Kidney Dis 2002; 40: 219-220
5. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J. On the relative safety of parenteral iron formulations. Nephrol Dial Transplant 2004 19: 1571-1575